Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Module 1 > Drug Development Process > Flashcards

Drug Development Process Flashcards

1
Q

What are the two main approahces to therapies in respiratory disease

A
  • Symptomatic Relief
    • Not disease modifying
  • Disease modifying/curative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Outline the pre-clinical drug development (after target identification)

A
  1. Synthesis of compounds
  2. Preliminary screening for pharmoclogical activity
  3. More pharmacology, Preliminary toxicology
  4. Selection of promising compounds
  5. Full animal pharmacology, subacute toxicology
  6. Preparation of formulations for human studies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some outcomes of interest when developing new compounds

A
  • Pharmacodynamics
    • Effect
    • Minimal Effective Dose
  • Pharmacokinetics
    • ADME
  • Toxicology
    • Adverse effects
    • NOEL - concentration of drug where no effect is seen on animal
    • NOAEL - Beneficial effects but no adverse effects
  • Mutagenicity
  • In vitro interaction potential
    • CP450
  • Reproductive and fertility studies
  • Carcinogenesis
    • Long-term toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some pre-requisites for studying drugs in humans

A
  • Adequate pre-clinical data
    • Safety
    • Toxicology
  • Appropriate drug formulation
  • Clinical rationale
  • Detailed study protocol
  • Risk-Benefit analysis
  • Ethics committee permission
  • Clinical Trials Registry Number
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the stages of a clinical trial and briefly explain what happens at each stage

A
  • Phase I
    • Healthy volunteers (Except in cancer as very toxic)
    • Safety and tolerance
  • Phase IIa
    • Small studies in patients
    • Tolerance, efficacy, PoP
  • Phase IIb
    • PoC and Dose-ranging study
    • 3 dosease vs placebo
  • Phase III
    • Larger efficacy studies in patients
    • Compared with established agents
  • Phase IV
    • Post-marketing studies to confirm safety, pharmacoeconomics and new indications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are some outcome measures for clinical trials and breifly explain them (6)

A
  • Proof of Mechanism
    • Show effect - mediator level
  • Proof of Principle
    • Pharmacological effect with a change in biomarker (Phase I/IIa)
  • Prood of concept
    • Pharmacological or clinical effect on well-validated disease marker/symptom
  • Symptomatic Efficacy
  • Functional Benefit
  • Disease Modification
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What subjects are used in Phase I trials?

A

Healthy human subjects

  • Usually not women as there is often no fetotoxicity data*
  • Healthy subjects cannot be used for Phase I when the drug is an anti-cancer as these are cytotoxic*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the starting dose used for Phase I trials

A

1/10 of the predicted dose on man

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the main primary outcome for Phase I studies (3)

A
  • Safety/Tolerance
  • Pharmacokinetics
    • Drug and food Interactions
  • PoM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What subjects are used for Phase II Studies

A

Patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the primary outcomes for Phase II (a and b) studies (4)

A
  • Pharmacokinetics
    • Side Effects
    • Toxicity
  • PoP/PoC
  • Efficacy vs placebo/active comparator
  • Optimal Dose
    • Dose-ranging
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What subjects are used in Phase II trials

A

Patients

Some additional use of animals for chronic toxicity and reproductive studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What study deisng do Phase II trials usually use

A

Double-blind randomised control

Against placebo and active comparator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the primary outcomes for Phase III trials

A
  • Efficacy
    • Functional
    • Symptomatic
  • Safety
    • Long-term tolerance >1 year
  • Risk:Benefit Ratio
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are some special safety considerations for drug development in asthma

A
  • Young:
    • Effects on growth
    • Pregnancy
  • Hyperractivity:
    • Inhaler-Induced bronchospasm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are some special safety considerations for drug development in COPD

A
  • Elderly:
    • Impaired drug metabolism
  • Polypharmacy
    • Interactions
17
Q

What are some special safety considerations for drug development in Cystic Fibrosis

A
  • Young:
    • Effect on growht
  • Malabsorption
    • Reduced oral drug efficacy
18
Q

What is the purpose of phase IV studies

A

Taken after drug is marketed:

  • Surveillance to detect unsuspected or long-term side effects
  • Further clinical studies to meet new regulations or obtain new indications
19
Q

Inhaled products are different from oral/IV drugs in their development. Describe these differences

A
  • Delivered topically
  • Generall lower dose (safer)
  • Device needs to pe proven as well as drug

Novel agents can be approved and given through existing devices, or standard agent via novel devices or novel agent and novel device

20
Q

When developing a new device, what kind of factors are being observed

A
  • Consistency
    • Same dose
    • Safety
  • Temperature and humidity effects
  • Particle Size
  • In vivo Lung deposition

Module 1 (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions